Product Image

Contributor Information

  • Name Anne Lykkesfeldt
  • Institute Danish Cancer Society

Tool Details

  • Tool name: MCF7/TAMR-1 Human Breast Cancer Cell Line
  • Tool type: Cell Lines
  • Tool sub-type: Continuous
  • Parental cell line: MCF7 S0.5
  • Organism: Human
  • Tissue: Breast
  • Cancer type: Breast cancer, tamoxifen-resistant
  • Disease: Cancer
  • Description: Tamoxifen resistant cell line which can be used to discover alternative treatments for breast cancer and understand the signalling pathways involved in tamoxifen resistance. Background and Research Application The MCF7/TAMR-1 Cell line is a breast cancer cell line resistant to tamoxifen. Tamoxifen is by far the most widely used drug for hormone-dependent breast cancer. However, primary or acquired resistance to Tamoxifen severely limits its clinical effectiveness. The MCF7/TAMR-1 cell line is a good model cell, to study the signalling pathways, which are the major drivers of tamoxifen-resistant growth. This cell line was produced as an adaptation of an original cell line (MCF7/S0.5), as a model cell system to study the effects of tamoxifen resistant cancer growth. This enables, identification of new hormone therapies and greater understanding of the signalling pathways/methods behind tamoxifen resistance.
  • Research area: Cancer ; Drug Discovery & Development

  • For Research Use Only

Target Details

Application Details

Handling

  • Format: Frozen
  • Growth medium: 37°C under 5% CO2 in air using phenol red-free DMEM:Ham's F-12 containing 1% fetal bovine serum, 2 mM Glutamax and 6 ng/ml insulin. To maintain high-level resistance, medium was supplemented with Tamoxifen (1 ?M).
  • Storage conditions: Liquid Nitrogen
  • Shipping conditions: Dry ice
  • Mycoplasma free: Yes
  • Biosafety level: 1

Documentation

  • Available on request

References

  •   Lee et al. 2018. Autophagy. 14(5):812-824. PMID: 29130361.
  •   Martin et al. 2017. Nat Commun. 8(1):1865. PMID: 29192207.
  •   An in vitro model for the development of acquired tamoxifen resistance.
  •   Guney Eskiler et al. 2016. Cell Biol Toxicol. :. PMID: 27585693.
  •   Joshi et al. 2016. Oncotarget. :. PMID: 27528030.
  •   Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer.
  •   ERa dimerization: a key factor for the weak estrogenic activity of an ERa modulator unable to compete with estradiol in binding assays.
  •   Leclercq et al. 2016. J Recept Signal Transduct Res. :1-18. PMID: 27400858.
  •   Guest et al. 2016. PLoS One. 11(6):e0157397. PMID: 27308830.
  •   Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
  •   High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.
  •   Alves et al. 2016. Clin Cancer Res. :. PMID: 27252418.
  •   Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755.
  •   Elias et al. 2015. Oncogene. 34(15):1919-27. PMID: 24882577.
  •   Thrane et al. 2014. Oncogene. PMID: 25362855.
  •   A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
  •   Differential response to a-oxoaldehydes in tamoxifen resistant MCF-7 breast cancer cells.
  •   Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy.
  •   Nass et al. 2014. PLoS One. 9(7):e101473. PMID: 24983248.
  •   Thrane et al. 2013. Breast Cancer Res Treat. 139(1):71-80. PMID: 23609470.
  •   Estrogen receptor a is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling.
  •   Cutrupi et al. 2012. Oncogene. 31(40):4353-61. PMID: 22249258.
  •   Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells.
  •   Plaza-Menacho et al. 2010. Oncogene. 29(33):4648-57. PMID: 20531297.
  •   Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.
  •   Lykkesfeldt et al. 1994. Cancer Res. 54(6):1587-95. PMID: 8137264.
  •   Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
  •   Lykkesfeldt et al. 1986. Br J Cancer. 53(1):29-35. PMID: 3947513.
  •   Indirect mechanism of oestradiol stimulation of cell proliferation of human breast cancer cell lines.